Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria
Status:
Not yet recruiting
Trial end date:
2023-03-03
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the impact of proteinuria on the
pharmacokinetic (PK) of a single dose of ALXN1720 in participants with proteinuria.